CANADA — Nanostics Inc., a precision health company specialising in diagnostic tests through its ClarityDX® platform technology, has partnered with OncoHelix, a leader in precision diagnostics, to bring ClarityDX Prostate® to healthcare providers and men in the Middle East.
This collaboration aims to improve prostate cancer screening in the region by offering an advanced diagnostic tool that combines biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer.
The availability of Clarity Prostate marks a significant advancement in early detection, enabling men and their healthcare providers to make more informed decisions about whether to proceed with a biopsy after an elevated prostate-specific antigen (PSA) test or abnormal digital rectal examination (DRE).
OncoHelix, headquartered in Burjeel Medical City, Abu Dhabi, provides molecular diagnostics and immune profile testing across the Middle East and North Africa (MENA) region through its cutting-edge laboratory, OncoHelix-coLAB.
This state-of-the-art facility is a joint venture between OncoHelix and Burjeel Holdings, one of the largest healthcare providers in the Middle East.
With the addition of ClarityDX Prostate to their diagnostic offerings, men in the region at risk of aggressive prostate cancer will benefit from more precise and timely diagnostics, ultimately leading to improved treatment outcomes.
In his remarks, Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta, emphasized the global relevance of Alberta-developed technologies.
He noted that partnering with OncoHelix to introduce ClarityDX Prostate to the Middle East highlights the international impact of their innovations.
He also highlighted that ClarityDX Prostate serves as a powerful diagnostic tool, capable of identifying aggressive prostate cancer early and improving long-term outcomes for men.
Faisal Khan, CEO of OncoHelix, echoed Dr. Lewis’ enthusiasm, expressing his excitement about the partnership with Nanostics.
Khan highlighted the value that ClarityDX Prostate brings to healthcare providers in the Middle East, allowing them to make more data-driven decisions and offer earlier, targeted treatments for men at risk of aggressive prostate cancer.
Currently, ClarityDX Prostate is available in the USA under the name CDX Prostate through Protean BioDiagnostics.
In Canada, the test is widely accessible in most provinces through Nanostics’ CPSA-accredited lab in Alberta, with additional testing services available in Quebec through CDL Laboratories.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE
